Compare Crispr Therapeutics AG (CRSP) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Manulife Financial Corporation — how do they compare? Crispr Therapeutics AG trades at $50.25 (market cap $4.97B), while Manulife Financial Corporation trades at $42.02 (market cap $68.68B). The key difference: Manulife Financial Corporation is far larger — about 13.8× Crispr Therapeutics AG's market cap, and Manulife Financial Corporation pays a 3.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MFC | |
|---|---|---|
Market Cap | $4.97B | $68.68B |
Sector | Health | Financials |
52-Week High | $76.78 | $41.69 |
52-Week Low | $44.34 | $29.90 |
Enterprise Value | $3.32B | $65.24B |
Dividend Yield | — | 3.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Manulife Financial (MFC) trades at $41.29, unchanged on the day, near its 52-week high. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal steady revenue growth to $53.01B in 2025 and a net income margin of 12.07%. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with 57% buy ratings. Key developments include a dividend payment and AI partnership expansions.
Outlook is cautiously optimistic with growth driven by Asia operations and AI initiatives, but risks include Q1 earnings miss and regulatory scrutiny. Valuation at P/E 16.89 and P/B 2.17 appears reasonable. Investors should monitor execution on earnings recovery and wealth management flows amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
